SBI Securities’s Travere Therapeutics TVTX Stock Holding History

SBI Securities’s Portfolio TVTX Stock Details TVTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$4.3K	Sell	73 -67	-48%	-$4.09K	﹤0.01%	2267
2026 Q2	$7.95K	Buy	140 +59	+73%	+$2.62K	﹤0.01%	1952
2026 Q1	$2.41K	Sell	81 -286	-78%	-$8.55K	﹤0.01%	2359
2025 Q4	$14K	Buy	367 +273	+290%	+$8.88K	﹤0.01%	1581
2025 Q3	$2.25K	Sell	94 -17	-15%	-$320	﹤0.01%	2380
2025 Q2	$1.64K	Buy	111 +28	+34%	+$464	﹤0.01%	2471
2025 Q1	$1.49K	Sell	83 -1	-1%	-$20	﹤0.01%	2421
2024 Q4	$1.46K	Buy	+84	New	+$1.49K	﹤0.01%	2435

Other funds holding TVTX

Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Stephens Investment Management Group Houston, Texas $9.29B AUM 41.16% 1-Year Est. Return

Emerald Advisers Leola, Pennsylvania $3.64B AUM 71.19% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return

Nuveen Charlotte, North Carolina $420B AUM 34.97% 1-Year Est. Return

Emerald Mutual Fund Advisers Trust Leola, Pennsylvania $2.45B AUM 70.46% 1-Year Est. Return

Russell Investments Group London, United Kingdom $114B AUM 33.83% 1-Year Est. Return

Fiera Capital (Canada) Montreal, Quebec, Canada $25.3B AUM 15.9% 1-Year Est. Return

Candriam SCA Strassen, Luxembourg, Luxembourg $22.5B AUM 50.38% 1-Year Est. Return

SBI Securities's TVTX Position: Q3 2026 in Review

SBI Securities reduced its Travere Therapeutics (TVTX) stake by 48% in Q3 2026, selling an estimated $4.09K and leaving 73 shares worth $4.3K. The position accounts for ﹤0.01% of the portfolio, ranked #2267.

SBI Securities first reported a position in TVTX in Q4 2024 and has held it in 8 quarters since. The position peaked at $14K in Q4 2025. 158 funds tracked by Wall St. Rank hold TVTX as of Q3 2026.

SBI Securities held 73 shares of Travere Therapeutics worth $4.3K as of Q3 2026.
SBI Securities sold 67 Travere Therapeutics shares in Q3 2026, an estimated $4.09K.
Travere Therapeutics made up ﹤0.01% of SBI Securities's portfolio in Q3 2026, its #2267 holding.
SBI Securities first reported a position in Travere Therapeutics in Q4 2024 and has held it in 8 quarters since.
SBI Securities's Travere Therapeutics position peaked at $14K in Q4 2025.
158 funds tracked by Wall St. Rank held Travere Therapeutics as of Q3 2026.

Based on SBI Securities's 13F filing for Q3 2026, filed 22 Oct 2026.